Trump's Medicaid freeze, Ozempic for kidney disease, and 23andMe for sale: Pharma news roundup
President Donald Trump's move to freeze federal funding for a massive number of government programs impacted Medicaid payment systems across the country, briefly locking 72 million Americans out of their health insurance Tuesday. Novo Nordisk said this week that its diabetes drug Ozempic was approved by the Food and Drug Administration (FDA) as the first GLP-1 treatment for chronic kidney disease. 23andMe (ME), the company that popularized consumer genetic testing, announced this week that it is once again exploring 'strategic alternatives,' which could include a potential sale of the company.
Check out those stories and more pharmaceutical news highlights from this week.
The U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesday that it would seek 'greater transparency' in drug price negotiations under President Donald Trump's administration. The statement follows criticism from the pharmaceutical industry regarding the program. 'As the second cycle begins under the Trump Administration, CMS is committed to incorporating lessons learned to date from the program and to considering opportunities to bring greater transparency in the Negotiation Program,' the agency said in a statement.
Read More
23andMe, the company that popularized consumer genetic testing, announced Tuesday that it is once again exploring 'strategic alternatives,' which could include a potential sale of the company or a restructuring. In a press release on Tuesday, the company said it needs additional liquidity to fund its operations and that 'management has determined that there is substantial doubt about the Company's ability to continue as a going concern.'
Read More
Novo Nordisk (NVO) announced today that its blockbuster drug Ozempic was approved by the Food and Drug Administration (FDA) as the first GLP-1 treatment for chronic kidney disease among people with type 2 diabetes. The popular diabetes drug can now be used to reduce the risk of kidney disease worsening, kidney failure, and death due to heart disease in adults with type 2 diabetes and chronic kidney disease.
Read More
President Donald Trump's move to freeze federal funding for a massive number of government programs seems to have impacted Medicaid payment systems across the country, potentially locking 72 million Americans out of their health insurance. Several lawmakers took to social media on Tuesday afternoon to confirm that their state's Medicaid payment systems have been shut off. 'The White House is aware of the Medicaid website portal outage. We have confirmed no payments have been affected — they are still being processed and sent,' White House spokesperson Karoline Leavitt wrote in a post on X on Tuesday.
Read More
Robert F. Kennedy Jr., President Donald Trump's nominee for health secretary, reportedly expressed openness to seizing drug patents of high-priced drugs as a way to lower prices. Politico reports that Kennedy indicated during a closed-door meeting with Senate Finance Committee staffers that he would consider adopting a proposal championed by progressive lawmakers like Senators Elizabeth Warren and Bernie Sanders. The outlet cited three unnamed sources familiar with the exchange.
Read More
The millennial-targeted telehealth company Hims & Hers (HIMS) is spending big bucks on its first-ever Super Bowl commercial to hawk its affordable weight-loss treatments. With Super Bowl ads reportedly costing about $7 million for a 30-second spot this year, Hims & Hers likely spent about $14 million for its one-minute commercial.
Read More
Pharmaceutical companies have already raised the price of over 800 brand-name prescription drugs this year. The increases apply to list prices before accounting for insurance, rebates to pharmacy benefit managers, or other discounts. This year's increases reflect a significant increase from Dec. 29 of last year, when drugmakers had shared plans to raise prices on just over 140 brands. More price hikes are also expected to be announced through the end of January, historically the busiest month for drugmakers to make increases.
Read More
LinkedIn (MSFT) co-founder and venture capitalist Reid Hoffman on Monday launched an AI startup aimed at discovering new treatments for cancer. Manas AI will use a proprietary AI-driven platform to help speed up the drug discovery process, from identifying potential drug candidates with 'paradigm-shifting speed and accuracy' all the way to clinical trials, Hoffman said in a press release. The company is initially focusing on treatments for breast cancer, prostate cancer, and lymphoma. Eventually, it intends to target other autoimmune diseases and rare conditions.
Read More
For the latest news, Facebook, Twitter and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
16 minutes ago
- Business Wire
Caring Together: Carefull to Partner with the Alzheimer's Association to Protect Families
NEW YORK--(BUSINESS WIRE)-- Carefull, the first financial safety platform built specifically for older adults and their families, is proud to support the Alzheimer's Association in raising awareness of the financial warning signs of cognitive decline and equipping families with tools to take early, protective action to prevent fraud and mistakes. Carefull is proud to support the care, services and research initiatives of the Alzheimer's Association. The Alzheimer's Association will provide information and resources aimed at helping families affected by dementia navigate financial challenges on Carefull's website. "Alzheimer's disease comes with a daily financial reality for families, and we are beyond proud to be working with the Alzheimer's Association to ensure financial safety is part of the cognitive health conversation" Share Designed to detect early behavioral signals and safeguard day-to-day finances, Carefull offers both a window into the early stages of cognitive change and a system to help preserve the financial independence and wellbeing of those affected. Carefull partners with financial institutions nationwide to bring these protections directly to the families they serve. Each year, more than 900,000 Americans develop Alzheimer's disease, with 7.2 million people aged 65 and older currently living with the condition. Behind each diagnosis is a network of loved ones offering critical support— nearly 12 million unpaid caregivers in the U.S. provide more than 19 billion hours of care annually for individuals with Alzheimer's or other dementias. 'We're committed to working with organizations that share our mission to protect and support older adults and their families. This effort is about helping families see what's happening sooner and act with confidence,' said Todd Rovak, Co-Founder of Carefull. 'Alzheimer's disease comes with a daily financial reality for families, and we are beyond proud to be working with the Alzheimer's Association to ensure financial safety is part of the cognitive health conversation.' Growing evidence shows that financial missteps—like missed bill payments, rising credit card debt, or unusual generosity—can signal early cognitive decline, including Alzheimer's. Research from institutions such as Johns Hopkins, Georgetown, and the National Institute on Aging suggests these behaviors may surface up to six years before a clinical diagnosis. Identifying these financial warning signs offers a powerful opportunity for early intervention and support. Carefull turns this insight into action, offering families and caregivers proactive tools that can detect behavioral changes in financial activity. Through real-time alerts, Carefull ScamCheck, trusted contact infrastructure, and an expert and empathetic care team, Carefull provides early signals that allow families to act before small issues become life-altering crises, and deploy a system to safeguard someone who may become vulnerable to inbound financial scams. Long before a diagnosis, subtle financial changes like missed bills, unusual spending, or increased vulnerability to scams, can be among the first signs that something is wrong. Early detection of Alzheimer's can make a significant difference in how families respond, plan, and care for a loved one. About Carefull Carefull is the first financial safety platform designed to protect aging adults and their families, from elder fraud, scams, and money mistakes. Built to support the unique needs of older adults, Carefull's proprietary AI provides 24/7 account monitoring, a suite of identity and home protections, along with expert resources to help families, advisors, and financial institutions safeguard families' financial well-being. Banks, credit unions, and wealth advisors use Carefull to deepen relationships across generations, provide proactive protection, and enhance trust with clients navigating both aging and financial caregiving for older adults. Recognized for its innovation in financial safety, Carefull partners with leading institutions to put financial care into financial services. Learn more at About the Alzheimer's Association The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit or call 800.272.3900.
Yahoo
23 minutes ago
- Yahoo
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
-- FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) -- -- Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator, will present topline del-brax data from dose escalation cohorts in oral presentation -- -- Stephen Tapscott, M.D., Ph.D., Professor of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, will highlight results on the characterization of a novel DUX4-regulated circulating biomarker in oral and poster presentations -- SAN DIEGO, June 11, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting two oral and one poster presentations at the 32nd Annual FSHD Society International Research Congress, being held June 12-13, 2025, in Amsterdam, the Netherlands. Earlier this week, Avidity announced FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD). 32nd Annual FSHD Society International Research Congress Presentations Topline Data from Dose Escalation Cohorts A and B in FORTITUDE™, a Phase 1/2 Trial Evaluating Del-brax (delpacibart braxlosiran) in Adults with Facioscapulohumeral Muscular Dystrophy (FSHD) Oral presentation: Jeffrey M. Statland, M.D., to present June 13, 2025, from 5:20 - 5:40 p.m. Central European Summer Time (CEST) / 11:20 - 11:40 a.m. ET Characterization of a promising DUX4-regulated circulating biomarker for facioscapulohumeral dystrophy (FSHD) Oral presentation: Stephen Tapscott, M.D., Ph.D., Professor of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, to present on June 12, 2025, from 6:25 - 6:30 p.m. CEST / 12:25 - 12:30 p.m. ET Poster presentation (#7.08): June 12, 2025, from 7:15 - 8:00 p.m. CEST / 1:15 - 2:00 p.m. ET The presentations and poster are available on the publications page of Avidity's website at About AvidityAvidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit and engage with us on LinkedIn and X. Forward-Looking StatementsAvidity cautions readers that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Avidity's plans to present topline data from the dose escalation cohorts of the Phase 1/2 FORTITUDE™ trial; the status and availability of accelerated and full approval pathways for del-brax and Avidity's planned participation at the 32nd Annual FSHD Society International Research Congress and the contents of its scheduled presentations. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of these plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Avidity's business and beyond its control, including, without limitation, the data and results produced from the clinical study of del-brax may not support BLA submission or accelerated or full approval, and may not be satisfactory to the FDA and other regulators; later developments with the FDA and other regulators may be inconsistent with the feedback received as of the date hereof; and the risks described in Avidity's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings with the SEC. Avidity cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that arise after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor Contact:Kat Lange(619) 837-5014investors@ Media Contact:Kristina Coppola (619) 837-5016media@ View original content to download multimedia: SOURCE Avidity Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Nvidia Teams With Novo Nordisk to Supercharge Early-Stage Drug R&D
June 11 - Novo Nordisk (NYSE:NVO) has teamed up with Nvidia (NASDAQ:NVDA) to integrate artificial intelligence into its drug development pipeline, aiming to speed up early-stage research, according to a Wednesday press release. The collaboration will build AI models tailored for Novo Nordisk's researchers, helping simulate and optimize early clinical trial stages. The tools are designed to support work across advanced simulation platforms and physical AI systems. Warning! GuruFocus has detected 4 Warning Signs with NVDA. This effort will also back Novo Nordisk's existing agreement with the Danish Centre for AI Innovation. That institution manages Gefion, Denmark's flagship AI supercomputer, which will play a key role in powering the new drug discovery tools. Nvidia said the initiative will apply generative and agent-based AI to pharmaceutical R&D. The announcement came during the chipmaker's GTC event in Paris, where it also highlighted broader partnerships across Europe. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
